March 28, 2025 02:50 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
3 cops killed, 2 terrorists shot dead during J&K's Kathua encounter: Report | Kolkata couple sues IVF centre for not revealing daughter's biological parents' identity, blames it for her death | 'India is not Dharamshala', Amit Shah says as Lok Sabha passes Immigration and Foreigners Bill 2025 | 'Now it's our turn': Vladimir Putin accepts Narendra Modi's invitation to visit India | Gold smuggling case: Kannada actor Ranya Rao’s bail plea rejected again | Congress workers clash with police in Odisha during protest against suspension of MLAs | Parvesh Verma and Atishi engage in war of words over 'bhai' comment in Delhi assembly | 'I am amused': Sitharaman on Raghav Chadha’s banking remarks, urges him to use ‘Western exposure’ for India | Mumbai Police denies Kunal Kamra more time to appear, issues second summons despite 'threat to life' claim | Political black comedy at its darkest: MK Stalin counters Yogi Adityanath on language row
Sputnik V
Wallpaper Cave

Sputnik V vaccine is more efficient against Delta variant of coronavirus: Study

| @indiablooms | Jun 16, 2021, at 12:01 am

Moscow: The Russia-developed Sputnik V vaccine has been found working efficiently against the Delta variant of the COVID-19 disease, a study revealed on Tuesday.

The variant of the disease was first reported from India.

The makers of the vaccine claimed that Sputnik V is working effectively against the variant than any other vaccine that published results on this strain so far.

Sputnik V's official Twitter handle posted: "#SputnikV is more efficient against the Delta variant of coronavirus, first detected in India than any other vaccine that published results on this strain so far - the Gamaleya Center study submitted for publication in an international peer-reviewed journal."

Meanwhile, a new analysis by PHE shows for the first time that 2 doses of COVID-19 vaccines are highly effective against hospitalisation from the Delta (B.1.617.2) variant, Public Health England said on Monday.

The analysis showed the Pfizer-BioNTech vaccine is 96 percent effective against hospitalisation after two doses.

Similarly, the Oxford-AstraZeneca vaccine is 92 percent effective against hospitalisation after 2 doses.

These are comparable with vaccine effectiveness against hospitalisation from the Alpha variant.

 Further work remains underway to establish the level of protection against mortality from the Delta variant. However, as with other variants, this is expected to be high.

The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised – between 12 April and 4 June, looking at emergency hospital admissions in England, PHE said in a statement.

Public Health England (PHE) has previously published analysis showing that one dose is 17 percent less effective at preventing symptomatic illness from the Delta variant, compared to Alpha, but there is only a small difference after 2 doses.

Health and Social Care Secretary Matt Hancock said: " This evidence of the effectiveness of two doses against variants shows just how crucial it is to get your second jab."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Close menu